Seamus Fernandez
Stock Analyst at Guggenheim
(4.94)
# 164
Out of 5,078 analysts
422
Total ratings
61.5%
Success rate
26.9%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Rated: Buy | $38 → $44 | $31.20 | +41.03% | 16 | Oct 19, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $143 | $89.27 | +60.19% | 16 | Oct 19, 2026 | |
| PCVX Vaxcyte | Reiterated: Buy | $125 | $60.43 | +106.85% | 16 | Oct 18, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $150 | $48.50 | +209.28% | 17 | Oct 12, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 | $61.48 | +21.99% | 51 | Oct 8, 2026 | |
| SGMT Sagimet Biosciences | Reiterated: Buy | $25 → $26 | $9.58 | +171.40% | 6 | Oct 1, 2026 | |
| IVA Inventiva | Reiterated: Buy | $14 | $3.71 | +277.36% | 8 | Sep 28, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,273 → $1,284 | $1,273.46 | +0.83% | 63 | Sep 17, 2026 | |
| TENX Tenax Therapeutics | Downgraded: Hold | n/a | $1.72 | - | 8 | Aug 31, 2026 | |
| AMLX Amylyx Pharmaceuticals | Rated: Buy | $55 → $57 | $27.20 | +109.56% | 11 | Aug 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $52 | $20.55 | +153.04% | 9 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 → $51 | $40.41 | +26.21% | 3 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $9.84 | - | 11 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | 16,500p → 16,200p | 12,824p | +26.33% | 20 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $41.60 | - | 13 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $12.41 | +141.74% | 3 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $3.75 | +220.00% | 4 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $140 | $21.19 | +560.69% | 7 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €110.00 → €101.00 | €74.12 | n/a | 10 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $39.05 | n/a | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.12 | n/a | 12 | Apr 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1,894.00 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $50.75 | n/a | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 → $130 | $145.27 | n/a | 36 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 → $83 | $24.03 | n/a | 5 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.6134 | n/a | 2 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $143.30 | n/a | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $128.00 | n/a | 4 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $151.12 | n/a | 16 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $3.08 | n/a | 1 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.40 | n/a | 2 | Sep 20, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $37 | $30.03 | n/a | 16 | Sep 8, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $10.89 | n/a | 1 | Aug 24, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 | $4.58 | n/a | 3 | Aug 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $224.03 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $439.26 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $805.02 | n/a | 1 | Jul 15, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $125 | $263.81 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $56 | $37.00 | n/a | 5 | Jun 13, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 | $29.25 | n/a | 1 | Mar 7, 2016 |
Arcutis Biotherapeutics
Oct 19, 2026
Rated: Buy
Price Target: $38 → $44
Current: $31.20
Upside: +41.03%
Rhythm Pharmaceuticals
Oct 19, 2026
Reiterated: Buy
Price Target: $143
Current: $89.27
Upside: +60.19%
Vaxcyte
Oct 18, 2026
Reiterated: Buy
Price Target: $125
Current: $60.43
Upside: +106.85%
MBX Biosciences
Oct 12, 2026
Reiterated: Buy
Price Target: $150
Current: $48.50
Upside: +209.28%
Bristol-Myers Squibb Company
Oct 8, 2026
Reiterated: Buy
Price Target: $75
Current: $61.48
Upside: +21.99%
Sagimet Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $25 → $26
Current: $9.58
Upside: +171.40%
Inventiva
Sep 28, 2026
Reiterated: Buy
Price Target: $14
Current: $3.71
Upside: +277.36%
Eli Lilly and Company
Sep 17, 2026
Reiterated: Buy
Price Target: $1,273 → $1,284
Current: $1,273.46
Upside: +0.83%
Tenax Therapeutics
Aug 31, 2026
Downgraded: Hold
Price Target: n/a
Current: $1.72
Upside: -
Amylyx Pharmaceuticals
Aug 26, 2026
Rated: Buy
Price Target: $55 → $57
Current: $27.20
Upside: +109.56%
Aug 12, 2026
Reiterated: Buy
Price Target: $48 → $52
Current: $20.55
Upside: +153.04%
Aug 11, 2026
Reiterated: Buy
Price Target: $45 → $51
Current: $40.41
Upside: +26.21%
Aug 6, 2026
Reiterated: Hold
Price Target: n/a
Current: $9.84
Upside: -
Jul 9, 2026
Reiterated: Buy
Price Target: 16,500p → 16,200p
Current: 12,824p
Upside: +26.33%
Jul 9, 2026
Reiterated: Hold
Price Target: n/a
Current: $41.60
Upside: -
Jun 24, 2026
Reiterated: Buy
Price Target: $30
Current: $12.41
Upside: +141.74%
May 11, 2026
Reiterated: Buy
Price Target: $12
Current: $3.75
Upside: +220.00%
May 7, 2026
Reiterated: Buy
Price Target: $140
Current: $21.19
Upside: +560.69%
Oct 8, 2025
Reiterated: Buy
Price Target: €110.00 → €101.00
Current: €74.12
Upside: n/a
Apr 17, 2025
Downgraded: Hold
Price Target: n/a
Current: $39.05
Upside: n/a
Apr 3, 2025
Rated: Hold
Price Target: n/a
Current: $2.12
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $1,894.00
Upside: n/a
Oct 31, 2024
Downgraded: Hold
Price Target: n/a
Current: $50.75
Upside: n/a
Jan 29, 2024
Reiterated: Buy
Price Target: $125 → $130
Current: $145.27
Upside: n/a
Oct 14, 2022
Reiterated: Buy
Price Target: $250 → $83
Current: $24.03
Upside: n/a
Dec 15, 2021
Downgraded: Hold
Price Target: n/a
Current: $0.6134
Upside: n/a
Dec 7, 2021
Downgraded: Hold
Price Target: n/a
Current: $143.30
Upside: n/a
Feb 25, 2020
Downgraded: Hold
Price Target: n/a
Current: $128.00
Upside: n/a
Oct 8, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $151.12
Upside: n/a
Oct 17, 2017
Initiated Coverage: Buy
Price Target: $13
Current: $3.08
Upside: n/a
Sep 20, 2016
Reiterated: Buy
Price Target: n/a
Current: $2.40
Upside: n/a
Sep 8, 2016
Reiterated: Hold
Price Target: $37
Current: $30.03
Upside: n/a
Aug 24, 2016
Reiterated: Buy
Price Target: $108
Current: $10.89
Upside: n/a
Aug 9, 2016
Reiterated: Buy
Price Target: $52
Current: $4.58
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $224.03
Upside: n/a
Jul 15, 2016
Rated: Hold
Price Target: n/a
Current: $439.26
Upside: n/a
Jul 15, 2016
Rated: Buy
Price Target: n/a
Current: $805.02
Upside: n/a
Jun 14, 2016
Reiterated: Buy
Price Target: $125
Current: $263.81
Upside: n/a
Jun 13, 2016
Reiterated: Hold
Price Target: $56
Current: $37.00
Upside: n/a
Mar 7, 2016
Downgraded: Hold
Price Target: $4
Current: $29.25
Upside: n/a